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Purpose: Bone regulation system may be affected after bariatric surgeries, but procedures impact
differently to bone mineral density (BMD) and measures restraining bone loss are frequently neglected
until clinical consequences become manifest. This is a systematic review aimed to elucidate whether
BMD loss is comparable after different bariatric surgeries. Materials and methods: A search of morbid
obese adults, undergone to bariatric surgery, with BMD measured by dual-energy X-ray absorptiometry
at baseline and after surgery studies was performed in several databases. Studies were assessed using the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement and
COCHRANE Risk of Bias tool. The random model was selected for meta-analysis; heterogeneity was
analyzed with T2, inconsistency (I2 > 50%) and Chi2 (p < 0.10). Level of evidence and strength of rec-
ommendations were summarized using the Grading of Recommendations, Assessment, Development
and Evaluation (GRADE System). Results: Twelve studies met the selection criteria. After one year,
reduction in total BMD in patients with mixed surgical procedures was signiﬁcant: 0.03 g/cm2 (CI 95%
0.00 to 0.06, p < 0.05). BMD was reduced by 0.12 g/cm2 (CI 95% 0.10 to 0.15, p < 0.001) in the
hip, 0.07 g/cm2 (CI 95% 0.03 to 0.11, p < 0.001) in the column, and 0.03 g/cm2 (IC 95% 0.02
to 0.04, p < 0.001) in the forearm, but not in restrictive surgeries. Studies included showed high het-
erogeneity and low quality of evidence. Conclusions: Patients undergone to mixed bariatric surgery had
signiﬁcant higher BMD deterioration as demonstrated in this review, suggesting that more attention for
preventing fractures is required.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.z-Carmona), ﬂas20@hotmail.
m (A.G. Gonzalez-Garay),
1@gmail.com (G. Melendez),
(A.E. Serralde-Zú~niga).
by Elsevier Ltd. All rights reserved1. Introduction
After years of debate, it was until recently that obesity was
recognized as disease and not as risk factor only [1]. Despite overt
evidence of its remarkable growing prevalence and its precedence
to other metabolic diseases, with serious consequences on organs.
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set under the interaction of genetics and environmental inﬂuences
[1,2] and associates to main causes of mortality and disability
around the globe [3]. Bariatric surgery has proved to be the most
effective therapy available for weight loss in morbid obesity and
provides additional beneﬁts on improvement or complete resolu-
tion of comorbidities [4].
In the hands of experienced surgical teams, post-operative
mortality accounts for less than 1% [5], but in the long term,
nutritional deﬁciencies may be unnoticed and lead to further
complications. Osteoporosis, Wernicke encephalopathy, anemia or
peripheral neuropathy [6,7] are among the hazards that may
develop if malabsorption importantly reduces nutrients ﬂow
through the intestinal wall.
In extremely obese subjects, mineral turnover is also affected,
beginning with obesity driven increased bone mass until before
operation and ending up with bone mass loss and increased risk of
fractures after weight reduction surgical procedures [8], unfortu-
nately, often are neither recognized nor treated [9]. Beside weight
loss, other factors play a role on inﬂuencing the risk of bone mass
loss: initial body weight, age, gender, physical activity, type 2 dia-
betes, Cushing disease or drug induced lipodystrophies [10].
Weight loss of any origin may trigger decline in bone mineral
density (BMD), it results from lower bearing weight and forceful
hormonal changes, that may be precipitated by low food intake and
malabsorption of essential nutrients, as it follows after weight
reduction surgical procedures [11]. Concomitantly, homeostasis of
vitamin D and calcium [7] are disrupted in obese patients before
surgery (often associated to secondary hyperparathyroidism) and
also may be aggravated after the procedures. Other factors playing
key roles on post-surgical bone loss are adipokines and gastroin-
testinal hormones peptide YY (PYY), glucagon like peptide 1 (GLP-
1); these hormones, beside their effect on hunger-satiety regula-
tion, inﬂuence bone homeostasis too [8].
Though dual-energy X-ray absorptiometry (DXA) is the standard
tool accepted to assess BMD and the potential risk of fracture [12],
major changes in fat mass distribution induced by weight loss may
affect the precision of BMD measurements in these patients [8].
Based upon the aforementioned evidence, it is crucial to setup
proper postsurgical monitoring protocols for these patients but
controversies still remain. The AACE/TOS/ASMBS (American Asso-
ciation of Clinical Endocrinologists, The Obesity Society and
American Society for Metabolic and Bariatric Surgery) sets forth
that patients undergoing into mixed procedures should have their
BMD monitored by axial hip and column (spine) DXA before and
two years post-surgery, whereas in patients going into restrictive
procedures DXA measurements can be taken after 2 years post-
surgery, only [13]. However, other groups recommend to have
DXA tests on a yearly basis [11]. Reports reviewing the relationship
between bariatric surgery and bonemetabolism are inconclusive as
their sample sizes are small, the time length of follow up varies
from 6 months to 2 years and are qualitative in essence. This sys-
tematic review is aimed to assess whether in morbidly obese pa-
tients, undergone to restrictive or mixed bariatric maneuvers, their
BMD equally declined after one year of bariatric surgery.
2. Methods
Studies including both male and female patients with morbid
obesity [preoperative Body Mass Index (BMI) 40 kg/m2 or BMI
35 kg/m2 associated to comorbidities], ages 18 years and over, who
had a bariatric surgery upon,with BMDmeasured by DXA at baseline
and one year post-operatory, were selected. The studies searched for
the analysiswere quasi-experimental, cohort or clinical trials. Articles
inwhichBMDwasmeasuredwithdevicesother thanDXAor inwhichpatients with restrictive surgery converted to a mixed procedure in
less than a yearwere excluded. Duplicate articles and articleswithout
clearly relevant data for our study were disregarded.
Eligible studies were searched across MEDLINE, EMBASE,
Cochrane-CENTRAL, WHOLIS and LILACS databases using the
following MeSH and entry terms: restrictive surgery [vertical
banded gastroplasty (VBG); sleeve gastrectomy; gastric banding/
adjustable gastric band, gastroplasty and laparoscopic gastro-
plasty]; mixed surgery [biliopancreatic diversion (BPD)/bil-
iopancreatic diversion with duodenal switch, jejunoileal bypass,
roux-in-y gastric bypass (RYGB)/gastric bypass/long limb roux in y
gastric bypass]; BMD (bone mineral density, bone density, bone
mass, bone loss, apparent bone mineral density, bone mineral
content, osteopenia and osteoporosis). The most recent search was
date March 2013.
Medline search strategy: #1 Descriptor MeSH Bone mineral
density. #2 Bone Density. #3 Bone mass. #4 Bone loss. #5 Osteopo-
rosis. #6. Osteopenia. #7 Bone mineral content. #8 Apparent bone
mineral density. #9 Gastroplasty. #10 Vertical banded gastroplasty.
#11 Sleeve gastrectomy. #12 Gastric banding. #13 Adjustable gastric
band. #14 Gastric bypass. #15 Roux-in-y gastric bypass. #16 Jeju-
noileal bypass. #17 Biliopancreatic diversion. #18 Biliopancreatic
diversion with duodenal switch. #19 Long limb roux in Y gastric
bypass. #20 Banded roux in Y gastric bypass. #21 (#1 OR #2 OR #3 OR
#4 OR #5 OR #6 OR #7 OR #8). #22 (#9 OR #10 OR #11 OR #12 OR
#13). #23 (#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20). #24
(#21 AND #22). #25 (#21 AND #23). #26 (#21 AND #22 AND #23).
#27 (#24 OR #25 OR #26).
The analysis and evaluation of risk of evidence bias were per-
formed by two separate reviewers and a third evaluator was
included to solve discrepancies, reviewers used the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE)
Statement and COCHRANE Risk of Bias tool for the analysis [14]; the
level of evidence and strength of recommendations were summa-
rized using the Grading of Recommendations, Assessment, Devel-
opment and Evaluation: (GRADE System). Data extractionwas done
independently by two reviewers using their own developed data-
base at Microsoft Excel 2010 (Redmond, Washington: Microsoft).
Selected variables included for the analysis were: type of surgery,
BMD changes (g/cm2 or percentage change) at total and different
body regions (hip, column, and forearm), weight (kg) and BMI (kg/
m2) difference between baseline and 1 year post-surgery and
whether supplements were used during the study period.
Data were entered into Review Manager Software [Computer
programversion 5.2. Copenhagen: The Nordic Cochrane Centre. The
Cochrane Collaboration, 2012] and the data exploratory process
was carried out by univariate analyses, appraising central tendency
summaries and distributions behavior. Subsequently, the random
effects model for the meta-analysis was selected to combine in-
formation and inspect heterogeneity among the studies. For
continuous data, all participants from each study were included
and mean differences were obtained. T2, inconsistency (I2, >50%)
and Chi2 (p < 0.10) tests were used to estimate heterogeneity. After
a ﬁrst assessment, subgroups were formed (type of surgery, study
period, supplementation) to reduce variation among the studies.
Statistical signiﬁcance was set at p < 0.05 [Online review protocol
does not exist, contact author for further information].
3. Results
We reviewed two hundred and ﬁfty six titles from databases
and another sources, ﬁfty were disregarded due to duplication
during the search. From the 206 articles identiﬁed, 167 were ruled
out for not meeting inclusion criteria. From the remaining 39 ar-
ticles, only twelve studies were included in the meta-analysis
Fig. 1. Flow diagram for locating studies for systematic review.
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[18e26]. Table 1 displays the studies speciﬁcs.
Baseline BMD was signiﬁcantly higher in the mixed group than
in the restrictive group (1.20 ± 0.2 g/cm2 vs 1.18 ± 0.06 g/cm2,
p < 0.05). After one year, total reduction of BMD in patients with
mixed surgical procedures was 0.03 g/cm2 (CI 95% 0.06 to 0.00,
p < 0.05; T2 ¼ 0.0, Chi2 p ¼ 0.25), whereas the restrictive group had
a positive change: þ0.04 g/cm2 (CI 95% 0.01 to þ0.08, p ¼ 0.16;
T2 ¼ 0.0, Chi2 p ¼ 0.06). Difference between groups was signiﬁcant
(p < 0.05).
BMD in the hip decreased by0.12 g/cm2 in themixed group (CI
95% 0.10 to 0.15, p < 0.001; T2 ¼ 0.0, Chi2 p ¼ 0.65) and 0.04 g/
cm2 in the restrictive group (CI 95% 0.09 to þ0.01, p ¼ 0.13;
T2 ¼ 0.0, Chi2 p ¼ 0.18). Subgroups difference was signiﬁcant
(p < 0.05).
BMD decline in the column in the mixed groupwas0.07 g/cm2
(CI 95% 0.03 to 0.11, p < 0.001; T2¼ 0.0, Chi2 p¼ 0.06) compared
to 0.01 g/cm2 in the restrictive group (CI 95% 0.07 to 0.09;
T2 ¼ 0.0, Chi2 p ¼ 0.25). There was not difference between groups
(p ¼ 0.06) (Fig. 2). BMD in the forearm in the mixed group was
reduced by0.03 g/cm2 (CI 95% 0.02 to0.04, p < 0.001, T2 ¼ 0.0,
Chi2 p ¼ 0.43) whereas the restrictive group showed 0.01 g/cm2
(CI 95%, 0.06 to þ0.05, p ¼ 0.86). Subgroups difference was not
signiﬁcant (p ¼ 0.38). Supplementation made no difference on the
outcomes before/after between groups.
Baseline weight was signiﬁcantly higher in the mixed group
than in the restrictive (124.5 ± 14.4 kg vs 115.6 ± 11.9 kg, p < 0.001).
BMIwas also higher at baseline in themixed group compared to therestrictive group, but its signiﬁcance was marginal (46.9 ± 6 kg/m2
vs 45.8 ± 4.8 kg/m2, p¼ 0.05). After twelve months, weight loss was
greater in the mixed group 41.04 kg (CI 95% 34.22 to 47.85,
p < 0.001; T2 154.51, Chi2 p < 0.001) than in the
restrictive 30.95 kg (CI 95% 19.3 to 42.6, p < 0.001; T2 133.58,
Chi2 p < 0.001) subgroup difference was not signiﬁcant (p ¼ 0.14)
(Fig. 3).
Heterogeneity in the twelve studies included was high and the
quality of evidence was low. The level of evidence and strength of
recommendations were summarized using GRADE system (Tables 2
and 3).
4. Discussion
Bariatric surgery has settled into the best therapeutic alternative
for morbid or grade II obesity with comorbidities. The experience of
skilled surgical teams has secured untoward post-operative events
be minimal [27], yet in the long term, safety data are still limited
[28]. Bone mineral content (BMC) decline and increased risk of
fractures has been reported as side effects with these procedures.
The relationship between the development of metabolic bone
disease and gastrointestinal surgery has been described since the
1970s and it has been recognized as a cause of osteomalacia and
minor-trauma related fractures [29]. Morbid obesity itself is related
to high BMC but once important weight loss is set (voluntary or
involuntary), it follows abatement in BMD. In the case of bariatric
surgeries, malabsorptive procedures have been related to dispro-
portionate reduction of BMD, when compared to less drastic
Table 1
Characteristics of studies included in the systematic review.
Study Design Surgery
type
Sup Y/
N
n (F/M) Age (years) BMI (kg/m2) Region measured
(n)
BMD (g/cm2)
Baseline 1 year Change (%) Baseline 1 year Change (%)
Ruíz Tovar 2013, Spain
(1)
QE R (LSG) N 42 (39/
3)
43.6 ± 10.1 51.2 ± 6.7 27.7 ± 2.1 24 (46) Total BMD (42) 1.18 ± 0.09 1.24 ± 0.08 0.06 (5)
Stein 2013, USA (2) QE M (RYGB) Y* 14 (14/
0)
45 ± 10 45 ± 5 e e Hip (14) e e e (8.1)
R** 8 (8/0) Hip (8) e e e (5.2)
Legro 2012, EUA (3) QE M (RYGB) N 29 (29/
0)
34.5 ± 4.3 49 ± 7 31 18 (38) Total BMD (29) 1.19 ± 0.08 1.19 0 (0)
Casagrande 2012, Brazil
(4)
QE M (RYGB) N 22 (22/
0)
37.2 ± 9.6 44.4 ± 12.8 27.5 ± 4.5 17 (38) Spine (22) 1.13 ± 0.11 1.04 ± 0.09 0.09 (8)
Hip (22) 1.03 ± 0.15 0.94 ± 0.16 0.09 (5.8)
Nogues 2010, Spain (5) RCT R (LSG) N 8 (8/0) 49.6 ± 9.6 43.5 ± 3.3 30.5 ± 2.6 13 (30) Spine (8) 1.013 ± 0.13 0.967 ± 0.13 0.05 (4.5)
Hip (8) 1.009 ± 0.07 0.936 ± 0.07 0.07 (7.2)
Forearm (8) 0.661 ± 0.60 0.656 ± 0.05 0.005
(0.8)
M (RYGB) 7 (7/0) 45.9 ± 8.6 43.1 ± 3.9 26.2 ± 2.7 17 (39) Spine (7) 1.1 ± 0.1 1.026 ± 0.07 0.07 (6.7)
Hip (7) 1.054 ± 0.07 0.929 ± 0.05 0.13
(11.8)
Forearm (7) 0.695 ± 0.07 0.693 ± 0.06 0.002(0.3)
Tsifsis 2009, Greece (6) RCT M (BPD) Y* 26 (26/
0)
30.3 ± 8 49.6 ± 6.4 30.4 ± 9.3 19 (39) Spine (26) 1.21 ± 0.05 1.114 ± 0.16 0.10 (7.9)
26 (26/
0)
34.8 ± 10.5 53.7 ± 9.2 32.9 ± 5.7 21 (39) Spine (26) 1.193 ± 0.14 1.113 ± 0.15 0.08 (6.7)
Carlin 2009, USA (7) RCT M (RYGB) Y 30 (30/
0)
43 ± 11.9 50.3 ± 4.9 32.5 ± 5.1 18 (39) Total BMD (12) e e 0.01
Spine (13) e e 0.01
Hip (13) e e 0.08
Forearm (17) e e 0.01
N 30 (30/
0)
42.9 ± 11.3 50.6 ± 6.6 32.7 ± 4.6 18 (36) Total BMD (17) e e 0.03
Spine (17) e e 0.03
Hip (17) e e 0.12
Forearm (23) e e 0.01
Carrasco 2009, Chile (8) QE M (RYGB) Y 42 (42/
0)
37.7 ± 9.6 45 ± 4.3 29.5 ± 3.9 15.5 (34.4) Total BMD (42) 1.23 ± 0.53 1.19 ± 0.63 0.04 (3.3)
Spine (42) 1.49 ± 0.11 1.38 ± 0.14 0.11 (7.4)
Hip (42) 1.28 ± 0.09 1.14 ± 0.09 0.14 (11)
Fleischer 2008, EUA (9) QE M (RYGB) Y 23 (18/
5)
20e64 47 ± 1.3 30.8 ± 1 16.2 (34.5) Spine (23) e e e (1.7)
Hip (23) e e e (8)
Forearm (23) e e e(0.3)
Mahdy 2008, Egypt (10) QE M (RYGB) Y 70 (49/
21)
35 ± 8.9 48 ± 7.3 32.6 ± 4.1 15 (32) Total BMD (70) 1.26 ± 0.03 1.22 ± 0.015 0.04 (3.2)
Pereira 2007, Brazil (11) QE M (RYGB) Y 8 (8/0) 37.8 ± 1.7 33.4 ± 1.6 e e Spine (8) 1.135 ± 0.04 1.108 ± 0.02 0.03(2.4)
Hip (8) 0.961 ± 0.04 0.849 ± 0.03 0.11
(11.7)
Forearm (8) 0.708 ± 0.01 0.678 ± 0.01 0.03 (4.2)
Giusti 2005, Switzerland
(12)
QE R (LAGB) N 37/0 35.7 ± 6.6 43.7 ± 4.1 e e Total BMD (37) 1.18 ± 0.08 1.19 ± 0.08 0.01 (0.8)
Spine (37) 1.1 ± 0.14 1.14 ± 0.19 0.04 (3.6)
Hip (37) 0.97 ± 0.08 0.95 ± 0.07 0.02 (2.3)
Design: RCT (Randomized controlled trial), QE (quasi-experimental). Surgery: R [laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB),
**unknown]; , M (Mixed: long limb biliopancreatic diversion (BPD), roux-en-y gastric bypass (RYGB)]. SUP (Supplementation): Y (yes), N (no), *The supplement was different
between the groups. BMI (body mass index). BMD (bone mineral density).
Fig. 2. Forest plot of hip and column BMD one year post bariatric mixed-procedure surgery.
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Fig. 3. Forest plot of weight loss one year post bariatric surgery.
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caloric restrictive diet, this is in agreement with previous publica-
tions where the use of restrictive procedures neither affected BMC
nor produced secondary hyperparathyroidism [15,23,30e34]. The
greater impact of mixed procedures on nutrients availability is due
to reduced food intake but is also accompanied by absorptive dis-
turbances resulting from deviations of physiologic food ﬂow,
delaying bolus mixing with pancreatic enzymes and/or biliary se-
cretions. If principal calcium absorption sites are removed, BMC is
in jeopardy and sometimes can lead to bone mass reduction. In
general, after a malabsorptive procedure, 10e25% of patients
develop calcium deﬁciency after 2 years and 25e48% after 4 years.
Vitamin D deﬁciency is present in 17e52% and 50e63%, respec-
tively [6,35e39].
Patients developing hyperparathyroidism are characterized by
vitamin D increased production, bone calcium resorption, osteo-
malacia [40] or secondary loss of BMD; these are all important
features associated to osteoporotic fractures, particularly in the hip
and column [41,42]. Low awareness on the prevalence of metabolic
bone disease after malabsorptive procedures has led The Endocrine
Society to recommend that patients going into malabsorptive
proceedings should have vitamin D, calcium, phosphorus, para-
thormone and alkaline phosphatase closely monitored every six
months, in addition, baseline DXA, and annually thereafter are
recommended until they reach stability [11]. The Bariatric Scientiﬁc
Collaborative Group (BSCG) has also underscored the importance of
having a preoperative BMD analysis [11,43]. These recommenda-
tions however, are not being implemented within protocols at
hospitals involved with bariatric surgeries, so there is no informa-
tion of BMD follow-up reports in many cases.
With regards to supplements that could have a direct impact on
bone health, the AACE/TOS/ASMBS recommend an early supple-
mentationwith vitamin D, at least 3000 IU per day, in patients who
undergo bariatric surgery. In the speciﬁc case of patients going into
RYGB, GS and LAGB, a preoperative determination of calcium is
advisable and the administration of 1200e1500 mg of essential
calcium is also recommended (in the diet or as a citrate supplement
divided in doses) [13]. The importance of these interventions and ofearly monitoring lies on preventing or detecting subclinical dis-
turbances prior to the DXA assessment.
Heterogeneity in the included studies (designs, surgical in-
terventions, supplementation and demographic characteristics of
subjects), is a major limiting factor in this systematic review.
Despite the fact that some studies have reported adequate patients'
compliance [39,44], this variable is not always an indicator of best
result in the treatment or prevention of vitamin D deﬁciency [45].
In order to better establish the relationship between the impact of
bariatric surgery in bone health and the efforts to prevent these
effects, such as standardization of supplementation and early
identiﬁcation of deterioration, further studies are required to
expand the information in this regard.
An important limitation of the articles reviewed in terms of
BMDmeasurement is the exclusion of individuals with bodyweight
over 300 pounds or 150 kg as individuals with this amount of
weight did not ﬁt into the central DXA units [46]. Only one study
[25] obtained peripheral measurement to eliminate bias; this could
have prevented signiﬁcant differences regarding weight loss
among the different procedures from being documented.
The mechanisms involved in the reduction of bone mass asso-
ciated to weight loss are still not clearly understood. Associated to
the phenomena that have a deleterious impact such as food intake
reduction, malabsorption, weight loss that reduced mechanical
load, there could be other factors that might promote beneﬁcial
effects on bone health. One of them is adiponectin, which serum
levels at 12 months after surgery show negative correlation with
the percentage of change in BMI [47]; likewise, levels of adipo-
nectin gradually increase, which reduce the number of osteoclast
and activate osteoblastogenesis [48]. One of the studies included in
the review [18] even reports an increase in BMD, which may have
modiﬁed the trends of our results.
There seems to be signiﬁcant reduction in BMD and BMI at one
year post surgery in patients who undergo mixed bariatric surgery;
thus, a comprehensive monitoring of these patients should be
performed according to international guidelines so as to reduce the
side effects of this effective therapeutic strategy against obesity
suggesting that more attention for preventing fractures is required.
Table 2
GRADE chart of changes in hip and spine BMD 1 year post bariatric mixed-procedure surgery.
Hip and spine BMD at 12 months after mixed surgery
Patient or population: patients with surgery
Settings: Hip and Spine BMD
Intervention: mixed surgery
Outcomes Illustrative comparative risksa (95% CI) Relative effect
(95% CI)
No of
participants
(studies)
Quality of the
evidence (GRADE)
Comments
Assumed risk Corresponding risk
Control BMD at 12 months later of mixed surgery
BMD g/cm2 The mean of BMD in the control
group was g/cm2
The mean of BMD in the intervention group was 0.09
higher (0.06e0.13 higher)
368 (5 studies) 4422 low1,2
BMDehip
g/cm2
Themean of hip BMD in the control
group was g/cm2
The mean of hip BMD in the intervention group was
0.12 higher (0.1e0.15 higher)
158 (4 studies) 4442
moderate3
BMD
espine
g/cm2
The mean of spine BMD in the
control group was g/cm2
The mean of spine BMD in the intervention group was
0.07 higher (0.03e0.11 higher)
210 (5 studies) 4422 low1,4
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conﬁdence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our conﬁdence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our conﬁdence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
a The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conﬁdence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Conﬁdence interval.
Table 3
GRADE table of weight loss one year after bariatric surgery.
Loss of weight at 12 months after surgery
Patient or population: patients with surgery
Settings: loss of weight at 12 months
Intervention: Restrictive surgery vs Mixed surgery
Outcomes Illustrative comparative risksa (95% CI) Relative
effect
(95% CI)
No of
participants(studies)
Quality of the
evidence(GRADE)
Comments
Assumed risk Corresponding risk
Control Weight loss at 12 months later of surgery
Weight at
12 months kg
The mean of weight at 12 months
in the control group was kg
The mean of weight at 12 months in the
intervention group was 38.16 higher (31.41e44.9
higher)
721 (12 studies) 4222 very
low1
Weight at 12
months e
Restrictive
surgery kg
The mean of weight at 12 months
e restrictive surgery in the control
group was kg
The mean of weight at 12 months e restrictive
surgery in the intervention group was 30.95
higher (19.28e42.62 higher)
190 (4 studies) 4222 very
low1,2,3
Weight at 12
months e
Mixed surgery
kg
The mean of weight at 12 months
e mixed surgery in the control
group was kg
Themean of weight at 12 monthsemixed surgery
in the intervention group was 41.04 higher (34.22
e47.85 higher)
531 (10 studies) 4222 very
low1,3
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conﬁdence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our conﬁdence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our conﬁdence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
a The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conﬁdence interval) is based
on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).CI: Conﬁdence interval.
Y. Rodríguez-Carmona et al. / International Journal of Surgery 12 (2014) 976e982 981Research in this ﬁeld is relevant because it will allow a better un-
derstanding of these phenomena, e.i. the mechanisms involved in
the loss of bone mineral density associated to bariatric surgery, and
the prevention of bone disease.
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